Comparison of efavirenz and protease inhibitor-based combination antiretroviral therapy regimens in treatment-naïve people living with HIV with baseline resistance-Reference-Cited by-同舟云学术

Comparison of efavirenz and protease inhibitor-based combination antiretroviral therapy regimens in treatment-naïve people living with HIV with baseline resistance

Published:2016-07-17 Issue:11 Volume:30 Page:1849-1852
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Lim Charlotte,McFaul Katie,Kabagambe Samuel,Sonecha Sonali,Jones Rachael,Asboe David,Pozniak Anton,Nwokolo Nneka,Boffito Marta

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference11 articles.

1. Transmitted antiretroviral resistance in a large HIV directorate 2011–2014: a response;McFaul;AIDS,2015

2. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways;Feng;Antimicrob Agents Chemother,2015

3. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients – impact of HIV subtypes and prior raltegravir experience;Garrido;Antiviral Res,2011

4. A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals;Schürmann;AIDS,2016

5. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients;Van Leeuwen;AIDS,2003

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current insights and molecular docking studies of HIV‐1 reverse transcriptase inhibitors;Chemical Biology & Drug Design;2023-10-10

2. Hepatitis B serological markers and plasma DNA concentrations;AIDS;2017-05-15